1-12 of 12
decitabine
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies

Clinical Trials & Observations
Anand A. Patel, Kirk Cahill, Caner Saygin, Olatoyosi Odenike
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2264–2271.
https://doi.org/10.1182/bloodadvances.2020002929
Published: 2021
Journal Articles

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Clinical Trials & Observations
Abhishek Maiti, Courtney D. DiNardo, Sa A. Wang, Jeffrey Jorgensen, Tapan M. Kadia, Naval G. Daver, Nicholas J. Short, Musa Yilmaz, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Alessandra Ferrajoli, Elias J. Jabbour, Nitin Jain, Guillermo Garcia-Manero, Maro Ohanian, Koichi Takahashi, Guillermo Montalban-Bravo, Lucia Masarova, Jan A. Burger, Philip A. Thompson, Srdan Verstovsek, Koji Sasaki, Michael Andreeff, Caitlin R. Rausch, Kathryn S. Montalbano, Sherry Pierce, Wei Qiao, Jing Ning, Hagop M. Kantarjian, Marina Y. Konopleva, Farhad Ravandi
Journal: Blood Advances
Blood Adv (2021) 5 (7): 1876–1883.
https://doi.org/10.1182/bloodadvances.2020003717
Published: 2021
Includes: Supplemental data
Journal Articles

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Clinical Trials & Observations
Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao, Jacob Glass, Amber C. King, Anthony F. Daniyan, Christopher Famulare, Bernadette M. Cuello, Troy Z. Horvat, Omar Abdel-Wahab, Ross L. Levine, Aaron D. Viny, Eytan M. Stein, Sheng F. Cai, Mikhail Roshal, Martin S. Tallman, Aaron D. Goldberg
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1552–1564.
https://doi.org/10.1182/bloodadvances.2020003734
Published: 2021
Includes: Supplemental data
Journal Articles

Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial

Clinical Trials & Observations
Yaqiong Tang, Jia Chen, Qifa Liu, Tiantian Chu, Tingting Pan, Jianying Liang, Xue Feng He, Feng Chen, Ting Yang, Xiao Ma, Xiaojin Wu, Shaoyan Hu, Xingyu Cao, Xiaohui Hu, Jiong Hu, Yuejun Liu, Jiaqian Qi, Yueping Shen, Changgeng Ruan, Yue Han, Depei Wu
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1250–1258.
https://doi.org/10.1182/bloodadvances.2020002790
Published: 2021
Includes: Supplemental data
Journal Articles

Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation

Clinical Trials & Observations
Burak Kalin, Yvette van Norden, Michel van Gelder, Dimitri Breems, Johan Maertens, Mojca Jongen-Lavrencic, Annoek E. C. Broers, Eric Braakman, Tim Grob, Wendelien Zeijlemaker, Gert J. Ossenkoppele, Ellen Meijer, Jan J. Cornelissen
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4430–4437.
https://doi.org/10.1182/bloodadvances.2020002074
Published: 2020
Includes: Supplemental data
Journal Articles

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Clinical Trials & Observations
Gerwin Huls, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Isabelle van Zeventer, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4267–4277.
https://doi.org/10.1182/bloodadvances.2020002846
Published: 2020
Includes: Supplemental data
Journal Articles

Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States

Clinical Trials & Observations
Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Rory M. Shallis, Nikolai A. Podoltsev, Jan P. Bewersdorf, Scott F. Huntington, Natalia Neparidze, Smith Giri, Steven D. Gore, Amy J. Davidoff, Xiaomei Ma
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2192–2201.
https://doi.org/10.1182/bloodadvances.2020001779
Published: 2020
Includes: Supplemental data
Journal Articles

TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC

Stacy Grieve, Gabriel Wajnberg, Miranda Lees, Simi Chacko, Jackson Weir, Nicolas Crapoulet, Tony Reiman
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3613–3625.
https://doi.org/10.1182/bloodadvances.2019000374
Published: 2019
Includes: Supplemental data
Journal Articles

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Clinical Trials & Observations
Gail J. Roboz, Sumithra J. Mandrekar, Pinkal Desai, Kristina Laumann, Alison R. Walker, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Eyal C. Attar, Wendy Stock, Clara D. Bloomfield, Jessica Kohlschmidt, Krzysztof Mrózek, Duane C. Hassane, Levi Garraway, Judit Jané-Valbuena, Michele Baltay, Adam Tracy, Guido Marcucci, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3608–3617.
https://doi.org/10.1182/bloodadvances.2018023689
Published: 2018
Includes: Supplemental data
Journal Articles

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms

Clinical Trials & Observations
Raajit K. Rampal, John O. Mascarenhas, Heidi E. Kosiorek, Leah Price, Dmitriy Berenzon, Elizabeth Hexner, Camille N. Abboud, Marina Kremyanskaya, Rona Singer Weinberg, Mohamed E. Salama, Kamal Menghrajani, Vesna Najfeld, Lonette Sandy, Mark L. Heaney, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck, Judith D. Goldberg, Ronald Hoffman
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3572–3580.
https://doi.org/10.1182/bloodadvances.2018019661
Published: 2018
Includes: Supplemental data
Journal Articles

Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy

Clinical Trials & Observations
Alex Aleshin, Peter L. Greenberg
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2787–2797.
https://doi.org/10.1182/bloodadvances.2018015834
Published: 2018
Journal Articles

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Clinical Trials & Observations
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, Raphael Itzykson, Ellen K. Ritchie, Mikkael A. Sekeres, John D. Barnard, Nikolai A. Podoltsev, Andrew M. Brunner, Rami S. Komrokji, Vijaya R. Bhatt, Aref Al-Kali, Thomas Cluzeau, Valeria Santini, Amir T. Fathi, Gail J. Roboz, Pierre Fenaux, Mark R. Litzow, Sarah Perreault, Tae Kon Kim, Thomas Prebet, Norbert Vey, Vivek Verma, Ulrich Germing, Juan Miguel Bergua, Josefina Serrano, Steven D. Gore, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2018) 2 (8): 923–932.
https://doi.org/10.1182/bloodadvances.2018016121
Published: 2018
Includes: Supplemental data